{"preliminary_commentary":{"by_channel":{"youtube":8,"podcast":3,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06952504\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["sacituzumab tirumotecan","pembrolizumab"]],"indication":"mismatch repair-proficient endometrial cancer, first-line maintenance","name":"TroFuse-033","nct_id":"NCT06952504","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trofuse-033-nct06952504. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TroFuse-033","arms":[{"description":"During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin area under the curve (AUC) 5 (mg/mL/min) or cisplatin 75 mg/m\\^2, and paclitaxel 175 mg/m\\^2 or docetaxel 75 mg/m\\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).\n\nDuring the Maintenance Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle and pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).","label":"Maintenance Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan","type":"EXPERIMENTAL"},{"description":"During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min) or cisplatin 75 mg/m\\^2, and paclitaxel 175 mg/m\\^2 or docetaxel 75 mg/m\\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).\n\nDuring the Maintenance Treatment Phase, participants receive pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).","label":"Maintenance Treatment Arm B: Pembrolizumab Monotherapy","type":"ACTIVE_COMPARATOR"},{"description":"During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min) or cisplatin 75 mg/m\\^2, and paclitaxel 175 mg/m\\^2 or docetaxel 75 mg/m\\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).\n\nDuring the Subsequent Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle until discontinuation criteria is met and pembrolizumab 400 mg on Day 1 of each 6-week cycle for up to 14 cycles (up to approximately 19 months).","label":"Subsequent Treatment Arm A: Pembrolizumab + Sacituzumab Tirumotecan","type":"EXPERIMENTAL"},{"description":"During the Induction Phase, participants receive pembrolizumab 200 mg, carboplatin AUC 5 (mg/mL/min) or cisplatin 75 mg/m\\^2, and paclitaxel 175 mg/m\\^2 or docetaxel 75 mg/m\\^2 on Day 1 of each 3-week cycle for 6 cycles (up to approximately 4 months).\n\nDuring the Subsequent Treatment Phase, participants receive sac-TMT 4 mg/kg on Days 1, 15, and 29 of each 6-week cycle until discontinuation criteria is met.","label":"Subsequent Treatment Arm B: Sacituzumab Tirumotecan Monotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2032-05-24","type":"ESTIMATED"},"conditions":["Endometrial Cancer"],"enrollment":{"count":1123,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["KEYTRUDA®","MK-3475","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Sacituzumab Tirumotecan","otherNames":["sac-TMT","MK-2870","SKB264"],"type":"BIOLOGICAL"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-10","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2032-05-24","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Maintenance Treatment: Progression-Free Survival (PFS)","timeFrame":"Up to approximately 44 months"},{"measure":"Maintenance Treatment: Overall Survival (OS)","timeFrame":"Up to approximately 54 months"}],"references":[],"start_date":{"date":"2025-05-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","url":"https://clinicaltrials.gov/study/NCT06952504"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trofuse-033-nct06952504"}